Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A disease due to a virus transmitted by an arthropod).
Biomarker and diagnostic research for Japanese encephalitis has been reported in the published literature.
No approved treatments are currently available for Japanese encephalitis. An additional 2 compounds hold orphan drug designation.
While no drugs are FDA-approved specifically for Japanese encephalitis, some of the following designated compounds may be used off-label in clinical practice. Treatment decisions should be made in consultation with a specialist familiar with this condition.
The following drugs have received orphan drug designation from the FDA for Japanese encephalitis. Orphan designation reflects regulatory interest and does not indicate approval for treatment.
Brand Name | Generic Name | Sponsor |
|---|
Estimated prevalence: Unknown (Unknown prevalence).
5 clinical trials registered, 1 recruiting. Interventions under study include other interventions and biologic therapy. Pipeline includes 2 PHASE4, 1 PHASE1. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT06674837](https://clinicaltrials.gov/study/NCT06674837) |
Data assembled from 5 of 12 sources · Last updated Sep 20, 2026, 2:11 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about Japanese encephalitis
Designated
Exclusivity End |
|---|
Designation Status |
|---|
IXIARO | Japanese encephalitis vaccine, inactivated, adsorbed | Intercell AG | 2012 | 2020 | Designated (drug approved for other indication) |
Japanese encephalitis vaccine (live, attenuated) | Japanese encephalitis vaccine (live, attenuated) | Glovax Co., Ltd. | 1999 | — | Designated |
Gene therapy approaches for Japanese encephalitis have been reported in the published literature.
5 trials found
Diagnostics and Surveillance of Acute Meningo-encephalitis Among Children in Cambodia With a Focus on Japanese Encephalitis Virus
— |
ANRS, Emerging Infectious Diseases |
NOT_YET_RECRUITING |
[NCT06678373](https://clinicaltrials.gov/study/NCT06678373) | Monitoring JE Antibody Levels in Healthy Populations and Immunization Strategy in Low-Prevalence Areas | PHASE4 | Liaoning Chengda Biotechnology CO., LTD | ACTIVE_NOT_RECRUITING |
[NCT06680128](https://clinicaltrials.gov/study/NCT06680128) | A Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis Messenger Ribonucleic Acid (mRNA) Vaccines (GBP560) in Healthy Adults | PHASE1 | SK Bioscience Co., Ltd. | UNKNOWN |
[NCT06825312](https://clinicaltrials.gov/study/NCT06825312) | Immunogenicity, Safety, and Antibody Persistence of Different Immunization Strategies Against Japanese Encephalitis | PHASE4 | Liaoning Chengda Biotechnology CO., LTD | ACTIVE_NOT_RECRUITING |
[NCT07358910](https://clinicaltrials.gov/study/NCT07358910) | Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective | — | Institut Pasteur du Cambodge | RECRUITING |
203 publications have been identified in PubMed for Japanese encephalitis. Research spans Basic Science / Preclinical (36%), Review / Meta-Analysis (26%), and Epidemiology / Natural History (21%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 74 | 36% |
Research summaries | 52 | 26% |
Disease patterns and progression | 42 | 21% |
New treatment approaches | 16 | 8% |
Clinical study results | 12 | 6% |
Testing and diagnosis research | 4 | 2% |
Patient case studies | 3 | 1% |
Liu R (2026). [PMID: 42096065](https://pubmed.ncbi.nlm.nih.gov/42096065/). *Vector Borne Zoonotic Dis*. [Basic Science / Preclinical]
Kumar M (2026). [PMID: 41135150](https://pubmed.ncbi.nlm.nih.gov/41135150/). *Virology*. [Gene Therapy / Novel Therapeutics]
Fan YC (2026). [PMID: 42080033](https://pubmed.ncbi.nlm.nih.gov/42080033/). *One Health*. [Epidemiology / Natural History]
Shaikh MS (2026). [PMID: 41863503](https://pubmed.ncbi.nlm.nih.gov/41863503/). *Recent Adv Antiinfect Drug Discov*. [Basic Science / Preclinical]
Causbie JM (2026). [PMID: 42025462](https://pubmed.ncbi.nlm.nih.gov/42025462/). *Dis Mon*. [Gene Therapy / Novel Therapeutics]
Li M (2026). [PMID: 41525861](https://pubmed.ncbi.nlm.nih.gov/41525861/). *Int J Biol Macromol*. [Review / Meta-Analysis]
Farsiu N (2026). [PMID: 42125402](https://pubmed.ncbi.nlm.nih.gov/42125402/). *Front Microbiol*. [Review / Meta-Analysis]
Yu L (2026). [PMID: 42170976](https://pubmed.ncbi.nlm.nih.gov/42170976/). *Pak J Pharm Sci*. [Review / Meta-Analysis]
Yan W (2026). [PMID: 42080820](https://pubmed.ncbi.nlm.nih.gov/42080820/). *J Med Virol*. [Epidemiology / Natural History]
Cho H (2026). [PMID: 42192599](https://pubmed.ncbi.nlm.nih.gov/42192599/). *Uisahak*. [Basic Science / Preclinical]
AI-curated news mentioning Japanese encephalitis
Updated Jun 12, 2026
A case report highlights coma as a complication of imported Japanese encephalitis, emphasizing the need for awareness in non-endemic regions. This finding contributes to the understanding of the disease's severe manifestations.